Vidatox is a drug produced from five protein peptides extracted from the venom of the blue scorpion (Rophalorus junceus), which is endemic to Cuba and which has analgesic, anti-inflammatory and anti-carcinogenic properties. The result of 15 years of research, by October last year Vidatox had been tested on more than 10,000 cancer patients, some 3,500 of them foreigners, with positive results both in improving quality of life and stopping tumour growth.
Labiofam, A Cuban pharmaceutical laboratory IS set to release a new “homeopathic” cancer drug to the international market. Marketed as Vidatox, it is the result of work by Cuban biologist, Misael Bordier with the venom of the blue scorpion. According to Isbel González, company's director of research and development, Vidatox is the result of 15 years of research and has been tested on more than 10,000 cancer patients, showing "positive results", ranging from "improved quality of life" to "slowed tumor growth".
González, said that Vidatox is a homeopathic preparation made from five protein peptides of low molecular weight extracted from the venom of the scorpion, and which has demonstrated an "analgesic, anti-inflammatory and anti-tumor effect in more than 15 different cancer cell lines."
The medication was produced from over 5,000 scorpions of the Rhopalurus junceus variety, native to eastern Cuba. According to the company, it has no contraindications and is compatible with any other oncological treatment.
The company presented the results of its Vidatox research in its first international congress in late September in Havana before some 500 delegates from all parts of the world.
The Company is all set to register its homeopathic version in coming days and go for its commercial production. The medication, and Labiofam says that its homeopathic version should be registered in the coming days and could be commercially produced immediately. González added that the company would continue research to produce synthetic or biotechnological versions of the compound.